Alexander Lesokhin, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a longer-term update of the safety and efficacy data of less frequent dosing of elranatamab in relapsed/refractory (R/R) patients with multiple myeloma (MM) enrolled in the MagnetisMM-3 study (NCT04649359). Dr Lesokhin notes that transitioning to every four-week dosing did not affect efficacy but reduced the incidence of adverse events (AEs) such as infections and GI side effects. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
